Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RemeGen Ltd.

https://remegen.com/

Latest From RemeGen Ltd.

China’s First ADC Secures Domestic Approval

RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.

China Approvals

China’s First ADC Secures Domestic Approval

RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.

China Approvals

China Inc. Shines In Latest Batch Of Approvals

Chinese domestic firms have gained a flurry of novel drug approvals at home, including the first globally for an anti-PD-1 antibody for nasopharyngeal carcinoma.

China Approvals

Lessons Learned And What's Ahead: I-Mab, JW, RemeGen CEOs On Biotech Financing

Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.

China Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register